All In Biotech

Drug Trial Radar · NCT07722546

A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old

A Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab Compared to Placebo in Adult Participants With Graves' Disease

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 30, 2026

Primary completion

Jan 31, 2028

Study completion Mar 31, 2028

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Jul 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about the use of felzartamab in participants with Graves' Disease, also known as GD. GD is an autoimmune disease, which means the body's immune system attacks its own healthy cells. In people with GD, the immune system produces abnormal antibodies, called thyroid-stimulating hormone receptor antibodies (TRAb), that attack the thyroid gland. This causes the thyroid to become too active and produce too much hormone, a condition called hyperthyroidism. Participants with GD are often treated with anti-thyroid drugs, or ATDs, which are medicines that help bring thyroid hormone levels back to normal. Felzartamab is designed to target certain immune cells that produce the abnormal TRAb antibodies. The main goal of the study is to learn whether felzartamab can help bring thyroid hormone levels back to normal and allow participants to stop taking ATDs. Participants will receive either felzartamab or placebo during the study. A placebo looks like the study drug but contains no real medicine. The main question that researchers want to answer is: • How many participants have normal thyroid levels without receiving any ATD medicine at Week 24? Researchers will also learn more about the safety of felzartamab and how the body processes the drug. The study will be done as follows: * Participants will be screened to check if they can join the study. * This is a double-blind study, which means neither the participants, study doctor, or site staff will know if participants are receiving felzartamab or a placebo. * Participants will be placed into 1 of 3 groups. Two groups will receive felzartamab while the other receives placebo. * Participants will receive felzartamab or placebo as intravenous (IV) infusions, which are slow injections into a vein using a needle. The Treatment Period will last 20 weeks. * During the Treatment Period, the study doctor may gradually lower the dose of the ATD if a participant's thyroid levels become normal. * Afterwards, participants will enter a follow-up period which will last 12 weeks. * In total, participants will have 22 study visits. Participants will stay in the study for about 9 months (up to 36 weeks).

Conditions

  • Graves' Disease

Interventions

  • FelzartamabDrug

    Administered IV

  • PlaceboDrug

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants who are Euthyroid and off Anti-Thyroid Drugs (ATD) at Week 24Time frame: At Week 24

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Sun City Clinical Research

    Glendale, Arizona · Recruiting

  • AME Clinical Research

    Los Angeles, California · Recruiting

  • San Jose Clinical Trials

    San Jose, California · Recruiting

  • DM Clinical Research

    Doral, Florida · Recruiting

  • LAMK Research and Health

    Hialeah, Florida · Recruiting

  • Floridian Clinical Research - Clinitiative

    Miami, Florida · Recruiting

  • Bioluminux Clinical Research

    Naperville, Illinois · Recruiting

  • Patient First Clinical Trials (PFCTrials)

    Lutherville, Maryland · Recruiting

  • Bioluminux Clinical Research

    Hamilton, New Jersey · Recruiting

  • Asheville Clinical Research

    Asheville, North Carolina · Recruiting

  • M3 Wake Research - Dallas

    Dallas, Texas · Recruiting

  • Gulf Coast Clinical Research

    Houston, Texas · Recruiting

  • Accurate Clinical Research, Inc

    Humble, Texas · Recruiting

  • Patient First Clinical Trials (PFCTrials)

    Richmond, Virginia · Recruiting

  • Solace Clinical Research - Puerto Rico

    Bayamón, Puerto Rico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.